Liquid chromatographic–tandem mass spectrometric determination of amprenavir (agenerase) in serum/plasma of human immunodeficiency virus type-1 infected patients receiving combination antiretroviral therapy
- 28 March 2001
- journal article
- research article
- Published by Elsevier in Journal of Chromatography A
- Vol. 914 (1-2) , 1-4
- https://doi.org/10.1016/s0021-9673(01)00607-0
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semenJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extractionJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoringAIDS, 1999
- Indinavir Concentrations and Antiviral EffectPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1999
- Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1998
- AmprenavirDrugs, 1998
- Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavirAIDS, 1997
- The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected PatientsAnnals of Internal Medicine, 1996